ArticleCurrent medicinal chemistry2025
Cartilage Oligomeric Matrix Protein: A Potential Prognostic Biomarker and Therapeutic Target in Gastric Cancer.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cartilage Oligomeric Matrix Protein (COMP) Correlates with Disease Progression, Selected Immune Checkpoint Molecules and SIGLEC9 in Colorectal Cancer.International journal of molecular sciences · 2026Article
- Using Disease Models for Mechanistic Studies: Special Focus on Gene Editing.Current medicinal chemistry · 2026Article
- COMP Is a Biomarker of Cartilage Destruction, Extracellular Matrix and Vascular Remodeling and Tissue Repair.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCartilage oligomeric matrix protein (COMP) is a protein that has been implicated in the development of some tumors, but its exact role in gastric cancer (GC) remains unclear.
objectiveThe study aims to comprehensively examine COMP in GC and to confirm its effects through experimental methods.
methodsThe research harnessed data from the Cancer Genome Atlas (TCGA) to explore the significance of COMP in GC and its potential as a diagnostic tool. The study also examined the regulatory networks involving COMP, including its interactions with immune cells, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and the stemness index based on mRNA expression (mRNAsi). Additionally, the study explored the relationship between COMP expression and drug sensitivity in GC. Genomic variations of COMP in GC were assessed. The expression of COMP was validated by the GEPIA2 tool and confirmed with quantitative reverse transcription PCR (qRT-PCR) in cell lines (normal human gastric epithelial cells GES-1 and GC cell lines AGS and HGC-27).
resultsAbnormal expression patterns of COMP were observed in various cancers, including GC. Higher levels of COMP in GC were significantly associated with the pathologic T stage and a history of reflux (p < 0.05 for both). Elevated COMP expression was correlated with poorer progression-free survival (PFS) (p = 0.027). COMP expression levels were identified as an independent prognostic factor for GC (p = 0.017). COMP was linked to TCF-dependent signaling in response to ECM receptor interaction, focal adhesion, and other pathways. There was an association between COMP expression and immune infiltration, immune checkpoint genes, TMB/MSI, and mRNAsi in GC. COMP expression was inversely correlated with the sensitivity to several drugs, indicating that higher levels of COMP may reduce the effectiveness of these drugs. COMP was found to be significantly up-regulated in GC cell lines.
conclusionsCOMP could serve as a prognostic biomarker and a potential therapeutic target for the treatment of GC.
Indexed as
Identifiers
40277122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.